heavier bleeding; nauseous; headache; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the ra. regulatory number: gb-mhra-webcovid-202202162221504080-gfhpf. other case identifier(s): gb-mhra-adr 26611751. a 24 year-old female patient (not pregnant) received bnt162b2 (comirnaty), administration date 11nov2021 (lot number: fh3220) as dose 1 , single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. patient has not had symptoms associated with covid-19. not had a covid-19 test. patient was not currently breastfeeding. the following information was reported: nausea (medically significant), outcome "recovered", described as "nauseous"; headache (medically significant), outcome "recovered", described as "headache"; heavy menstrual bleeding (medically significant), outcome "unknown", described as "heavier bleeding". the patient underwent the following laboratory tests and procedures: pregnancy test: negative. the patient had heavier bleeding after 1st covid vaccine, and period started 2 days early. after 1st dose, headache lasted 5 days and strong nauseous feeling, although not physically sick. patient has not tested positive for covid-19 since having the vaccine. patient is not enrolled in clinical trial. the report was not related to possible inflammation of the heart (myocarditis or pericarditis). patient last menstrual period date was on 08dec2021. the patient received second dose of comirnaty on 06jan2022. no follow-up attempts are possible. no further information is expected